Issues lobbied + lobbyists (4)
MMM — Medicare/Medicaid
All legislation related to Medicare site of service payment policy changes; the Cassidy Hassan Senate framework for hospital site neutral payments; Issues related to Medicare reimbursements for cancer services; Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals, including satellite regulations; Medicare Advantage preauthorization; Medicare Advantage access issues; Cuts to services related to cancer diagnosis and treatment; Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products; Policies related to the value of cancer care and initiatives that bend the cost curve; Issue related to site neutral payment reforms being included in the OBBB; Issues related to the FAIR Act and the work of the joint Taskforce developing a new method of cost reimbursement and federal grants.
Government entities lobbied: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE
BUD — Budget/Appropriations
Issues related to the President's upcoming federal budget request; Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI. The impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant recisions; Funding included in the CR packages that were passed.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
GOV — Government Issues
Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant terminations; the future of global health programs;
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
MED — Medical/Disease Research/Clinical Labs
Issues related to clinical trial design and patients obtaining drugs sooner in the course of the trial
Government entities lobbied: Food & Drug Administration (FDA)